SG Americas Securities LLC lessened its stake in Tilray Inc (NASDAQ:TLRY – Free Report) by 74.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 88,506 shares of the company’s stock after selling 256,734 shares during the quarter. SG Americas Securities LLC’s holdings in Tilray were worth $156,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Bank of Montreal Can raised its stake in Tilray by 19.6% during the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after buying an additional 355,778 shares in the last quarter. Lazard Asset Management LLC bought a new position in Tilray during the first quarter worth $118,000. Avantax Advisory Services Inc. boosted its holdings in Tilray by 46.2% in the first quarter. Avantax Advisory Services Inc. now owns 53,110 shares of the company’s stock worth $131,000 after purchasing an additional 16,792 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in shares of Tilray during the first quarter worth $75,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Tilray by 11.5% during the second quarter. The Manufacturers Life Insurance Company now owns 682,478 shares of the company’s stock worth $1,131,000 after purchasing an additional 70,605 shares during the period. Institutional investors own 9.35% of the company’s stock.
Tilray Trading Down 2.4 %
Shares of NASDAQ TLRY opened at $1.64 on Friday. Tilray Inc has a 12-month low of $1.45 and a 12-month high of $2.97. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -3.73 and a beta of 2.13. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. The stock’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $1.80.
Analysts Set New Price Targets
Separately, Roth Mkm decreased their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a report on Friday, October 11th.
Read Our Latest Stock Analysis on TLRY
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Articles
- Five stocks we like better than Tilray
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is the Euro STOXX 50 Index?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Are Dividends? Buy the Best Dividend Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.